Trials / Completed
CompletedNCT01670929
Pr-conceptional Progesterone for Unexplained Recurrent Miscarriage
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 700 (actual)
- Sponsor
- Woman's Health University Hospital, Egypt · Academic / Other
- Sex
- Female
- Age
- 20 Years – 39 Years
- Healthy volunteers
- Not accepted
Summary
In women with unexplained recurrent miscarriages, progesterone (400 mg pessaries, twice daily), started soon as possible at luteal phase and after a positive pregnancy test and continued to 28 weeks of gestation, compared to placebo, ).
Detailed description
Progesterone improves secondary outcomes such as gestation at delivery, on-going pregnancy at 12 weeks, survival at 28 days of neonatal life. . Progesterone, compared to placebo, does not incur substantial adverse effects to the mother or the neonate. Explore differential or subgroup effects of progesterone in prognostic subgroups. . Perform an economic evaluation for cost-effectiveness.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Progesterone | |
| OTHER | Placebo |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2015-05-01
- Completion
- 2015-11-01
- First posted
- 2012-08-22
- Last updated
- 2016-04-05
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT01670929. Inclusion in this directory is not an endorsement.